1. Home
  2. UBXG vs XCUR Comparison

UBXG vs XCUR Comparison

Compare UBXG & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U-BX Technology Ltd. Ordinary Shares

UBXG

U-BX Technology Ltd. Ordinary Shares

N/A

Current Price

$4.84

Market Cap

12.6M

Sector

N/A

ML Signal

N/A

XCUR

Exicure Inc.

HOLD

Current Price

$1.75

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBXG
XCUR
Founded
2018
2011
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
13.7M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
UBXG
XCUR
Price
$4.84
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.4M
42.3K
Earning Date
06-18-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
83.37
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.68
52 Week High
$12.88
$9.50

Technical Indicators

Market Signals
Indicator
UBXG
XCUR
Relative Strength Index (RSI) N/A 33.71
Support Level N/A $1.71
Resistance Level N/A $3.40
Average True Range (ATR) 0.00 0.32
MACD 0.00 -0.03
Stochastic Oscillator 0.00 7.89

Price Performance

Historical Comparison
UBXG
XCUR

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: